Stockscreener 앱 받기
12.50
5.31%
0.63
전일 마감가:
$11.87
열려 있는:
$11.88
하루 거래량:
5.72M
Relative Volume:
0.87
시가총액:
$1.45B
수익:
$52.86M
순이익/손실:
$-480.19M
주가수익비율:
-2.6653
EPS:
-4.6899
순현금흐름:
$-421.82M
1주 성능:
+20.42%
1개월 성능:
+37.06%
6개월 성능:
+4.52%
1년 성능:
+32.70%
1일 변동 폭
$11.70
$12.75
1주일 범위
$10.14
$12.75
52주 변동 폭
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
NTLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.50 | 1.37B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-10-28 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD - Stocktwits
Intellia Therapeutics (NTLA) Stock: Cathie Wood’s ARK Buys Third Day Running - Blockonomi
Sumitomo Mitsui Trust Group Inc. Sells 316,409 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NTLA) Stock: Cathie Wood Continues Three-Day Buying Streak - CoinCentral
Cathie Wood’s ARK made just one buy last session — and it’s a biotech stock up nearly 30% YTD - MSN
Cathie Wood’s ARK adds to Intellia stock holdings on January 15 By Investing.com - Investing.com South Africa
ARK Investment Increases Stake in Intellia Therapeutics (NTLA) - GuruFocus
Cathie Wood’s ARK adds to Intellia stock holdings on January 15 - Investing.com India
ARK Invest Acquires 56,769 Shares of Intellia, Stock Rises 2% - Intellectia AI
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death - Yahoo Finance
Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety EventHas The Bull Case Changed? - Sahm
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clinical Hold On Lead Gene Editing Trial - Sahm
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Best Nasdaq Stocks Clinical Innovation - Kalkine Media
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
SG Americas Securities LLC Acquires 92,485 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
cathie wood’s ARK stock buys INTELLIA, continues trend By Investing.com - Investing.com Nigeria
cathie wood’s ARK stock buys INTELLIA, continues trend - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 6.9%Still a Buy? - MarketBeat
cathie wood’s ARK stock trades highlight intellia, personalis buys By Investing.com - Investing.com Australia
cathie wood’s ARK stock trades highlight intellia, personalis buys - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Roche Holding AG (RHHVF) - The Globe and Mail
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares - sharewise.com
Fred Cohen Buys 303% More Intellia Therapeutics Shares - Yahoo Finance
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina By Investing.com - Investing.com Canada
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina - Investing.com
Intellia Updates Investors on Nex-Z Trial Safety Hold - TipRanks
Intellia Therapeutics, Inc. Updates on Clinical Trials and Regulatory Plans - TradingView — Track All Markets
Why Intellia Therapeutics Inc. (38I) stock fits value portfoliosMarket Movement Recap & AI Optimized Trade Strategies - ulpravda.ru
CEO Change: Is Intellia Therapeutics Inc. stock a defensive play in 2025Wall Street Watch & Safe Capital Allocation Plans - ulpravda.ru
How Intellia Therapeutics Inc. stock benefits from global expansion2025 Earnings Surprises & Safe Swing Trade Setups - ulpravda.ru
Buyback Watch: Can Intellia Therapeutics Inc. stock beat market expectations this quarterWeekly Trend Report & Free Long-Term Investment Growth Plans - ulpravda.ru
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap UpTime to Buy? - MarketBeat
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Insider Buying: Fred Cohen Acquires 150,000 Shares of Intellia T - GuruFocus
Intellia Therapeutics (NASDAQ:NTLA) CEO John Leonard Sells 34,146 Shares of Stock - MarketBeat
Intellia Therapeutics Insider Sold Shares Worth $314,485, According to a Recent SEC Filing - marketscreener.com
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics
Intellia Therapeutics prepares for JPM Healthcare Conference presentation - Traders Union
44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics
Gene editing firm Intellia to share CRISPR work at major health event - Stock Titan
What analysts say about Intellia Therapeutics Inc 38I stockUtilities Sector Analysis & Identify Ideal Buy Points With Precision - earlytimes.in
Why Intellia Therapeutics (NTLA) Is Down After FDA Halts Key CRISPR Trial Over Safety Concerns – And What's Next - Sahm
BofA Adjusts Price Target on Intellia Therapeutics to $12 From $14, Maintains Neutral Rating - marketscreener.com
Intellia Stock Declines Around 55% in 3 Months: Here's Why - Finviz
Intellia Therapeutics reports inducement grants - Medical Buyer
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully - Yahoo Finance
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Intellia Therapeutics Inc 주식 (NTLA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schultes Birgit C | EVP, Chief Scientific Officer |
Jan 05 '26 |
Sale |
9.21 |
8,508 |
78,359 |
98,533 |
| BASTA JAMES | EVP, General Counsel |
Jan 05 '26 |
Sale |
9.21 |
10,397 |
95,756 |
101,528 |
| Cohen Fred E | Director |
Jan 05 '26 |
Buy |
9.35 |
150,000 |
1,402,500 |
207,453 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 05 '26 |
Sale |
9.21 |
11,903 |
109,627 |
121,249 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 05 '26 |
Sale |
9.21 |
9,515 |
87,633 |
87,118 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jan 05 '26 |
Sale |
9.21 |
6,379 |
58,751 |
99,683 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 05 '26 |
Sale |
9.21 |
2,989 |
27,529 |
52,277 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Option Exercise |
6.83 |
49,959 |
341,220 |
1,127,074 |
| LEONARD JOHN M | President and CEO |
Dec 12 '25 |
Option Exercise |
6.83 |
8,557 |
58,444 |
1,047,485 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Sale |
9.49 |
88,146 |
836,384 |
1,038,928 |
4.73%
0.92%
자본화:
|
볼륨(24시간):